- Home
- BKT vs ITOS Comparison
BKT vs ITOS Comparison
Compare BKT & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BKT
- ITOS
- Stock Information
- Founded
- BKT 1988
- ITOS 2011
- Country
- BKT United States
- ITOS United States
- Employees
- BKT N/A
- ITOS N/A
- Industry
- BKT Investment Bankers/Brokers/Service
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BKT Finance
- ITOS Health Care
- Exchange
- BKT Nasdaq
- ITOS Nasdaq
- Market Cap
- BKT 247.8M
- ITOS 270.7M
- IPO Year
- BKT N/A
- ITOS 2020
- Fundamental
- Price
- BKT $11.69
- ITOS $6.67
- Analyst Decision
- BKT
- ITOS Strong Buy
- Analyst Count
- BKT 0
- ITOS 3
- Target Price
- BKT N/A
- ITOS $25.67
- AVG Volume (30 Days)
- BKT 67.9K
- ITOS 550.0K
- Earning Date
- BKT 01-01-0001
- ITOS 04-28-2025
- Dividend Yield
- BKT 8.97%
- ITOS N/A
- EPS Growth
- BKT N/A
- ITOS N/A
- EPS
- BKT N/A
- ITOS N/A
- Revenue
- BKT N/A
- ITOS $35,000,000.00
- Revenue This Year
- BKT N/A
- ITOS N/A
- Revenue Next Year
- BKT N/A
- ITOS $31.74
- P/E Ratio
- BKT N/A
- ITOS N/A
- Revenue Growth
- BKT N/A
- ITOS 177.89
- 52 Week Low
- BKT $10.55
- ITOS $4.80
- 52 Week High
- BKT $12.92
- ITOS $18.75
- Technical
- Relative Strength Index (RSI)
- BKT 55.42
- ITOS 49.00
- Support Level
- BKT $11.49
- ITOS $6.18
- Resistance Level
- BKT $11.73
- ITOS $7.80
- Average True Range (ATR)
- BKT 0.13
- ITOS 0.50
- MACD
- BKT 0.02
- ITOS -0.05
- Stochastic Oscillator
- BKT 73.08
- ITOS 29.94
About BKT BlackRock Income Trust Inc. (The)
Blackrock Income Trust Inc is a diversified investment fund with an investment objective to manage a portfolio of high-quality securities to achieve both preservations of capital and high monthly income. The trust seeks to achieve its investment objective by investing at least 65 percent of its assets in mortgage-backed securities. The Fund invests at least 80 percent of its assets in securities that are (i) issued or guaranteed by the U.S. government or one of its agencies or instrumentalities or (ii) rated at the time of investment either AAA by S&P Global Ratings (S&P) or Aaa by Moody's Investors Service, Inc (Moody's). The Fund may invest directly in such securities or synthetically through the use of derivatives.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.